Ann: Collaboration with PEPSCAN , page-4

I hear you BZH - i think Phylogica as hinted at in many of the collaborations formed with other biotechnology companies uses CD40 as a test mark - as they always imply the use of the tech for other "un-named" targets - more like a quiet cover....

The more i read about CLIPS the more interesting it is...

Pepscan wouldn't attract an Advisory Board of this kind of calibre for a technology that doesn't hold a high level of interest....



Sir Gregory Winter is a scientific pioneer of protein engineering and therapeutic monoclonal antibodies. He invented techniques to make humanized and fully human antibodies for therapeutic uses. His technology is used in over two-thirds of the antibody products on the market. He is a founder of Cambridge Antibody Technology (acquired by AstraZeneca) and also a founder of Domantis (acquired by GSK). In 2009 he co-founded Bicycle Therapeutics, a licensee of Pepscan aiming to develop small protein mimics. Greg Winter is Deputy Director at the Laboratory of Molecular Biology, Cambridge. He is also Deputy Director of the MRCs Centre for Protein Engineering. Winter has received numerous prizes and awards and was knighted in 2004 for his services to science.

Dr. Andrew Hamilton is the Vice-Chancellor of the University of Oxford since 2009. He is the former Provost of Yale and served as chairman of the department of chemistry at Yale. Hamilton obtained his PhD from Cambridge University and was assistant professor of Chemistry at Princeton University and professor of chemistry at the University of Pittsburgh. His research interests lie at the interface of organic and biological chemistry, with particular focus on the use of synthetic design for the understanding, mimicry, and potential disruption of biological processes. His lab is most noted for the design of barbiturate hosts, farnesyl tranferase inhibitors, protein surface binders, and helix mimetics.